Waldenstrom macroglobulinemia: Genomic aberrations and treatment

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Waldenström macroglobulinemia (WM) is a rare, indolent, and monoclonal immunoglobulin M-associated lymphoplasmacytic disorder with unique clinicopathologic characteristics. Over the past decade, remarkable progress has occurred on both the diagnostic and therapeutic fronts in WM. A deeper understanding of the disease biology emanates from the seminal discoveries of myeloid differentiation primary response 88 (MYD88) L265P somatic mutation in the vast majority of cases and C-X-C chemokine receptor, type 4, mutations in about a third of patients. Although WM remains an incurable malignancy, and the indications to initiate treatment are largely unchanged, the therapeutic armamentarium continues to expand. Acknowledging the paucity of high-level evidence from large randomized controlled trials, herein, we evaluate the genomic aberrations and provide a strategic framework for the management in the frontline as well as the relapsed/refractory settings of symptomatic WM.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherKluwer Academic Publishers
Pages321-361
Number of pages41
Volume169
DOIs
StatePublished - 2016

Publication series

NameCancer Treatment and Research
Volume169
ISSN (Print)09273042

Fingerprint

Waldenstrom Macroglobulinemia
CXC Chemokines
Mutation
Chemokine Receptors
Therapeutics
Immunoglobulin M
Randomized Controlled Trials
Neoplasms

Keywords

  • BTK inhibitors
  • CXCR4
  • IgM
  • MYD88
  • Waldenstrom’s macroglobulinemia

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Kapoor, P., Ansell, S. M., & Braggio, E. D. (2016). Waldenstrom macroglobulinemia: Genomic aberrations and treatment. In Cancer Treatment and Research (Vol. 169, pp. 321-361). (Cancer Treatment and Research; Vol. 169). Kluwer Academic Publishers. https://doi.org/10.1007/978-3-319-40320-5_16

Waldenstrom macroglobulinemia : Genomic aberrations and treatment. / Kapoor, Prashant; Ansell, Stephen Maxted; Braggio, Esteban D.

Cancer Treatment and Research. Vol. 169 Kluwer Academic Publishers, 2016. p. 321-361 (Cancer Treatment and Research; Vol. 169).

Research output: Chapter in Book/Report/Conference proceedingChapter

Kapoor, P, Ansell, SM & Braggio, ED 2016, Waldenstrom macroglobulinemia: Genomic aberrations and treatment. in Cancer Treatment and Research. vol. 169, Cancer Treatment and Research, vol. 169, Kluwer Academic Publishers, pp. 321-361. https://doi.org/10.1007/978-3-319-40320-5_16
Kapoor P, Ansell SM, Braggio ED. Waldenstrom macroglobulinemia: Genomic aberrations and treatment. In Cancer Treatment and Research. Vol. 169. Kluwer Academic Publishers. 2016. p. 321-361. (Cancer Treatment and Research). https://doi.org/10.1007/978-3-319-40320-5_16
Kapoor, Prashant ; Ansell, Stephen Maxted ; Braggio, Esteban D. / Waldenstrom macroglobulinemia : Genomic aberrations and treatment. Cancer Treatment and Research. Vol. 169 Kluwer Academic Publishers, 2016. pp. 321-361 (Cancer Treatment and Research).
@inbook{6148ce60d7aa49b98f53066e931ee413,
title = "Waldenstrom macroglobulinemia: Genomic aberrations and treatment",
abstract = "Waldenstr{\"o}m macroglobulinemia (WM) is a rare, indolent, and monoclonal immunoglobulin M-associated lymphoplasmacytic disorder with unique clinicopathologic characteristics. Over the past decade, remarkable progress has occurred on both the diagnostic and therapeutic fronts in WM. A deeper understanding of the disease biology emanates from the seminal discoveries of myeloid differentiation primary response 88 (MYD88) L265P somatic mutation in the vast majority of cases and C-X-C chemokine receptor, type 4, mutations in about a third of patients. Although WM remains an incurable malignancy, and the indications to initiate treatment are largely unchanged, the therapeutic armamentarium continues to expand. Acknowledging the paucity of high-level evidence from large randomized controlled trials, herein, we evaluate the genomic aberrations and provide a strategic framework for the management in the frontline as well as the relapsed/refractory settings of symptomatic WM.",
keywords = "BTK inhibitors, CXCR4, IgM, MYD88, Waldenstrom’s macroglobulinemia",
author = "Prashant Kapoor and Ansell, {Stephen Maxted} and Braggio, {Esteban D}",
year = "2016",
doi = "10.1007/978-3-319-40320-5_16",
language = "English (US)",
volume = "169",
series = "Cancer Treatment and Research",
publisher = "Kluwer Academic Publishers",
pages = "321--361",
booktitle = "Cancer Treatment and Research",
address = "Netherlands",

}

TY - CHAP

T1 - Waldenstrom macroglobulinemia

T2 - Genomic aberrations and treatment

AU - Kapoor, Prashant

AU - Ansell, Stephen Maxted

AU - Braggio, Esteban D

PY - 2016

Y1 - 2016

N2 - Waldenström macroglobulinemia (WM) is a rare, indolent, and monoclonal immunoglobulin M-associated lymphoplasmacytic disorder with unique clinicopathologic characteristics. Over the past decade, remarkable progress has occurred on both the diagnostic and therapeutic fronts in WM. A deeper understanding of the disease biology emanates from the seminal discoveries of myeloid differentiation primary response 88 (MYD88) L265P somatic mutation in the vast majority of cases and C-X-C chemokine receptor, type 4, mutations in about a third of patients. Although WM remains an incurable malignancy, and the indications to initiate treatment are largely unchanged, the therapeutic armamentarium continues to expand. Acknowledging the paucity of high-level evidence from large randomized controlled trials, herein, we evaluate the genomic aberrations and provide a strategic framework for the management in the frontline as well as the relapsed/refractory settings of symptomatic WM.

AB - Waldenström macroglobulinemia (WM) is a rare, indolent, and monoclonal immunoglobulin M-associated lymphoplasmacytic disorder with unique clinicopathologic characteristics. Over the past decade, remarkable progress has occurred on both the diagnostic and therapeutic fronts in WM. A deeper understanding of the disease biology emanates from the seminal discoveries of myeloid differentiation primary response 88 (MYD88) L265P somatic mutation in the vast majority of cases and C-X-C chemokine receptor, type 4, mutations in about a third of patients. Although WM remains an incurable malignancy, and the indications to initiate treatment are largely unchanged, the therapeutic armamentarium continues to expand. Acknowledging the paucity of high-level evidence from large randomized controlled trials, herein, we evaluate the genomic aberrations and provide a strategic framework for the management in the frontline as well as the relapsed/refractory settings of symptomatic WM.

KW - BTK inhibitors

KW - CXCR4

KW - IgM

KW - MYD88

KW - Waldenstrom’s macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=84989827545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989827545&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-40320-5_16

DO - 10.1007/978-3-319-40320-5_16

M3 - Chapter

C2 - 27696269

AN - SCOPUS:84989827545

VL - 169

T3 - Cancer Treatment and Research

SP - 321

EP - 361

BT - Cancer Treatment and Research

PB - Kluwer Academic Publishers

ER -